


# PF-04449913

**ALTERNATE NAME:** N-[(2R,4R)-2-(1H-benzimidazol-2-yl)-1-methyl-4-piperidinyl]-N'-(4-cyanophenyl)-urea

**CATALOG #:** B2467-1 1 mg  
B2467-5 5 mg

**STRUCTURE:**



**MOLECULAR FORMULA:** C<sub>21</sub> H<sub>22</sub> N<sub>6</sub> O

**MOLECULAR WEIGHT:** 374.4

**CAS NUMBER:** 1095173-27-5

**APPEARANCE:** Crystalline solid

**PURITY:** ≥98% by HPLC

**STORAGE:** Store at -20°C.

**SOLUBILITY:** ~20 mg/ml DMSO

**DESCRIPTION:** PF-04449913 is a potent and orally bioavailable smoothened (SMO) inhibitor. PF-04449913 binds to human SMO with an IC<sub>50</sub> of 4 nM. It has been shown to attenuate leukemia stem cell self-renewal and cell cycle progression in primary acute myeloid leukemia cells and in an in vivo Drosophila model.

**REFERENCES:** Munchhof, M.J., et al. (2011). ACS Med. Chem. Lett. 3(2), 106-111.

**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

**RELATED PRODUCTS:**

Smo Antagonist, SA9 (2155)  
SANT-1 (1978)  
LY-2940680 (9604)  
LDE-225 (2892)  
Smo Antagonist, SA10 (2159)  
Smo Antagonist, SA1 (2154)

**DISCLAIMER:** *FOR RESEARCH USE ONLY! Not to be used on humans.*